Canaccord analyst John Young raised the firm’s price target on Merit Medical to $102 from $100 and keeps a Buy rating on the shares. The firm updated its model following the release of its preliminary Q4 and 2023 results.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MMSI:
- Merit Medical enrolls first patient in Motion study
- First Patient Enrolled in Merit Medical’s MOTION Study
- Merit Medical enrolls first patient in MOTION study
- Merit Medical price target raised to $95 from $88 at Piper Sandler
- Merit Medical Announces Projected Preliminary Unaudited Revenue for the Year Ended December 31, 2023 and Plans to Announce Fourth Quarter and Year End 2023 Results and Issue Fiscal Year 2024 Guidance on February 28, 2024
